LOS ANGELES, CA--(Marketwired - Dec 19, 2016) - Endonovo Therapeutics, Inc. ( OTCQB : ENDV ) ("Endonovo" or the "Company"
"The Company had previously announced receiving a term sheet for $5 million in preferred financing from a strategic healthcare investor to develop a pipeline in vascular diseases, peripheral artery disease and ischemia/reperfusion injury. The $5 million proposed financing is part of a larger $15 million round of financing to uplist the Company's common stock onto a national stock exchange in the first half of 2017".